中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (10): 2310-2320.doi: 10.4103/1673-5374.391303

• 原著:视神经损伤修复保护与再生 • 上一篇    

全球糖尿病眼病研究趋势:2012至2021年的数据

  

  • 出版日期:2024-10-15 发布日期:2024-01-29

Global trends in diabetic eye disease research from 2012 to 2021

Yuan Yuan1, Shangli Ji2, 3, Yali Song4, Zhaodi Che4, Lu Xiao4, Shibo Tang2, 3, *, §, Jia Xiao2, 3, 4, *, §   

  1. 1Aier School of Ophthalmology, Central South University, Changsha, Hunan Province, China; 2Changsha Aier Eye Hospital, Changsha, Hunan Province, China; 3Aier Eye Institute, Changsha, Hunan Province, China; 4Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China
  • Online:2024-10-15 Published:2024-01-29
  • Contact: Shibo Tang, MD, PhD, tangshibo@vip.163.com; Jia Xiao, PhD, edwinsiu@connect.hku.hk.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 82122009 (to JX);Science Research Foundation of Aier Eye Hospital Group, No. AM2001D1 (to JX); and the Natural Science Foundation of Hunan Province, No. 2020JJ5002 (to SJ). None of the funding bodies play any role in the study other than to provide funding.

摘要:

糖尿病眼病(DED)是糖尿病患者的一组眼部并发症,包括糖尿病视网膜病变(DR)、糖尿病黄斑水肿(DME)、糖尿病白内障(DC)和糖尿病青光眼(DG),其最新的全球流行病学信息尚需进一步完善。文章收集了美国、中国、日本、英国、西班牙、德国和法国这7个国家与 DED 相关的研究基金信息;所有 DED 期刊论文均来自 Web of Science 和 PubMed 数据库;所有注册临床试验均来自 ClinicalTrials 数据库,以及 2012-2021 年期间美国、中国、日本和欧盟机构批准的新药信息。2012-2021 年间,在 2288 项有关 DED 的政府研究基金中,DR 占了绝大多数(89.53%),其次是 DME(9.27%)。美国提供了最多的研究经费。在不同的国家,DR 和 DME 拨款的研究目标多种多样。此外,美国在研究成果方面占主导地位,发表的论文占全球 DED 论文的 17.53%,被引用次数占总数的 22.58%。美国和英国在 DED 研究方面的国际合作居于领先地位。在415项临床试验中,DME是药物开发的主要疾病(58.19%)。大约一半的试验(49.13%)是关于血管生成的。然而,获批的眼科药物(1830 项中的 40 项,占 2.19%)和 DED 药物(1830 项中的 3 项,占 0.02%)数量很少。说明过去十年中,与 DED 相关的基础研究和转化研究并不活跃;新的治疗方法和新批准的药物很少。

https://orcid.org/0000-0003-2737-6780 (Shibo Tang); https://orcid.org/0000-0001-5647-4190 (Jia Xiao)

Abstract: Diabetic eye disease refers to a group of eye complications that occur in diabetic patients and include diabetic retinopathy, diabetic macular edema, diabetic cataracts, and diabetic glaucoma. However, the global epidemiology of these conditions has not been well characterized. In this study, we collected information on diabetic eye disease-related research grants from seven representative countries––the United States, China, Japan, the United Kingdom, Spain, Germany, and France––by searching for all global diabetic eye disease journal articles in the Web of Science and PubMed databases, all global registered clinical trials in the ClinicalTrials database, and new drugs approved by the United States, China, Japan, and EU agencies from 2012 to 2021. During this time period, diabetic retinopathy accounted for the vast majority (89.53%) of the 2288 government research grants that were funded to investigate diabetic eye disease, followed by diabetic macular edema (9.27%). The United States granted the most research funding for diabetic eye disease out of the seven countries assessed. The research objectives of grants focusing on diabetic retinopathy and diabetic macular edema differed by country. Additionally, the United States was dominant in terms of research output, publishing 17.53% of global papers about diabetic eye disease and receiving 22.58% of total citations. The United States and the United Kingdom led international collaborations in research into diabetic eye disease. Of the 415 clinical trials that we identified, diabetic macular edema was the major disease that was targeted for drug development (58.19%). Approximately half of the trials (49.13%) pertained to angiogenesis. However, few drugs were approved for ophthalmic (40 out of 1830; 2.19%) and diabetic eye disease (3 out of 1830; 0.02%) applications. Our findings show that basic and translational research related to diabetic eye disease in the past decade has not been highly active, and has yielded few new treatment methods and newly approved drugs.

Key words: clinical trials, diabetic cataracts, diabetic eye disease, diabetic glaucoma, diabetic macular edema, diabetic retinopathy, drug development, global research, publication, research grant